Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KTFHO
ADC Name	CN111330016A ADC-1
Synonyms	CN111330016A_ADC-1 Click to Show/Hide
Organization	Agensys Inc.; Seagen Inc.
Drug Status	Investigative
Indication	In total 1 Indication(s) Bladder cancer [ICD11:2C94] Investigative
Drug-to-Antibody Ratio	6
	3D MOL	2D MOL
Antibody Name	Ha15-10ac12		Antibody Info
Antigen Name	SLIT and NTRK-like protein 6 (SLITRK6)		Antigen Info
Payload Name	Undisclosed
Linker Name	CN111330016A ADC-1 linker

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 83.1	%	Undisclosed	Undisclosed
Tumor Growth Inhibition value (TGI)	≈ 95.7	%	Undisclosed	Undisclosed
Tumor Growth Inhibition value (TGI)	≈ 96.3	%	Undisclosed	Undisclosed

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 83.10% (Day 20)	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 3 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ11-031)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 95.70% (Day 29)	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ09-083)
Experiment 3 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 96.30% (Day 36)	Positive SLITRK6 expression (SLITRK6+++/++)
Method Description	All treatments were conducted at day 0 by a single dose, i.v, 10 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
In Vivo Model	Bladder cancer PDX model (PDX: SQ09-041)

References

Ref 1	Antibody Drug Conjugates (ADC) that bind to 158P1D7 protein.